Início › Leucemia Linfocítica Crônica › Ohio

Ensaios clínicos de Leucemia Linfocítica Crônica em Ohio

43 estudos para Leucemia Linfocítica Crônica estão buscando participantes em locais em Ohio.

Cidades em Ohio

Texto oficial do estudo (Inglês)

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

Cleveland Clinic Akron General, Akron
OhioHealth O'Bleness Hospital, Athens
Avon - Richard E Jacobs Health Center, Avon
e mais 16

RecrutandoFase 3

Idades 65 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT07321652

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Summa Health System - Akron Campus, Akron
Cleveland Clinic Akron General, Akron
Summa Health System - Barberton Campus, Barberton
e mais 44

RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos

Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069

A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

Study Site 104, Columbus

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT07582432

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland
Cleveland Clinic Foundation, Cleveland
Ohio State University Comprehensive Cancer Center, Columbus
e mais 2

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT04269902

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

GC2202 Study Site 105, Canton

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT05645107

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Oncology Hematology Care Clinical Trials, Llc, Cincinnati

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT06943872

Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia

Ohio State University Comprehensive Cancer Center, Columbus

RecrutandoFase 2

Idades 75 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT07685717

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

University Hospitals, Cleveland
Dayton Physician Network, Dayton

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT06846671

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Dayton Physician Network, Dayton

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT06973187

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Oncology Hematology Care Inc, Cincinnati

RecrutandoFase 4

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07218341

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

University of Cincinnati Medical Center, Cincinnati

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT07648264

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

University of Cincinnati, Cincinnati
The Cleveland Clinic Foundation, Cleveland
The Ohio State University, Columbus
e mais 1

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT07221500

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

Ohio State University Comprehensive Cancer Center, Columbus

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 11 de set. de 2026 · NCT07061951

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, Cleveland
Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 9 de set. de 2026 · NCT07225439

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

Research Site, Columbus

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT06564038

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

The James Cancer Hospital and Solove Research Institute, Columbus

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT05091424

Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Ohio State University Comprehensive Cancer Center, Columbus

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 31 de ago. de 2026 · NCT07734038

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

University of Cincinnatti Medical Center, Cincinnatti

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 17 de ago. de 2026 · NCT06528301

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

OSU Comprehensive Cancer Center, Columbus

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 11 de ago. de 2026 · NCT07342478

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

The Ohio State University Wexner Medical Center, Columbus

RecrutandoFase 1/2

Idades de 13 a 90 · Todos os sexos · Atualizado em 6 de ago. de 2026 · NCT06533579

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

University of Cincinnati, Cincinnati
The Ohio State University, Columbus

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 31 de jul. de 2026 · NCT06708897

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

University of Cincinnati Medical Center, Cincinnati
Cleveland Clinic, Cleveland

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 2 de jul. de 2026 · NCT05131022

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

Ohio State University Comprehensive Cancer Center, Columbus

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 12 de jun. de 2026 · NCT07271667

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Nationwide Children's Hospital, Columbus
Ohio State University Comprehensive Cancer Center, Columbus

RecrutandoFase 1

Idades 2 e acima · Todos os sexos · Atualizado em 29 de mai. de 2026 · NCT05418088

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Cincinnati Children's Hospital Medical Center, Cincinnati
University of Cincinnati, Cincinnati
The Ohio State University, Columbus

RecrutandoFase 1

Idades 13 e acima · Todos os sexos · Atualizado em 5 de mai. de 2026 · NCT04771572

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

Gabrail Cancer Center Research,, Canton

RecrutandoFase 1/2

Idades de 12 a 95 · Todos os sexos · Atualizado em 15 de abr. de 2026 · NCT04329728

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Cleveland Clinic Main Campus /ID# 271292, Cleveland

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 9 de abr. de 2026 · NCT06428019

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Ohio State University Comprehensive Cancer Center, Columbus

RecrutandoFase 4

Idades 18 e acima · Todos os sexos · Atualizado em 2 de mar. de 2026 · NCT06876662

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Ohio State University Comprehensive Cancer Center, Columbus

RecrutandoFase 4

Idades 18 e acima · Todos os sexos · Atualizado em 2 de mar. de 2026 · NCT06876649

Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi

Ohio State University Comprehensive Cancer Center, Columbus

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 19 de fev. de 2026 · NCT06466122

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

Ohio State University Comprehensive Cancer Center, Columbus

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 19 de fev. de 2026 · NCT05336812

Study of SGR-1505 in Mature B-Cell Neoplasms

Gabrail Cancer & Research Center, Canton
The Ohio State University - The James Cancer Hospital, Columbus

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 13 de fev. de 2026 · NCT05544019

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

The Ohio State University /ID# 230439, Columbus

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 9 de fev. de 2026 · NCT04895436

Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia

Ohio State University Comprehensive Cancer Center, Columbus

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 7 de jan. de 2026 · NCT05417165

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

The Ohio State University Comprehensive Cancer Center, Columbus

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 7 de jan. de 2026 · NCT06043674

Study of Epcoritamab as a Consolidation Therapy in CLL/SLL

University of Cincinnati, Cincinnati

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 6 de jan. de 2026 · NCT07108998

Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

University of Cincinnati, Cincinnati

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 6 de jan. de 2026 · NCT07014917

Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Ohio State University Comprehensive Cancer Center, Columbus

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 16 de dez. de 2025 · NCT06757647

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Taylor Cancer Research Center, Maumee

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 10 de dez. de 2025 · NCT05602363

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

University Hospitals Cleveland Medical Center, Cleveland
The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2025 · NCT05780034

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.